Ferronova has a team of leading Australasian researchers and clinicians overseen by an experienced board and CEO.
Stewart Bartlett, CEO
Stewart was a co-founder of medical device company Signostics. From 2005-2017 he was COO of Signostics, managing product development, manufacturing, quality, regulatory, customer service, OEM partnerships, and at various times sales and marketing. Prior to Signostics, he held several management positions at Lake Technology Ltd, including managing director of a subsidiary responsible for licensing Lake’s technology. He has worked in a variety of management, engineering and sales and marketing roles in Australia, the United States, and Europe, and holds a Bachelor of Electrical Engineering with Honors from Curtin University and a Master of Business Administration from The Australian Graduate School of Management.
Dr Anil Shetty, CMO
Dr Shetty is the Chief Medical Officer and manages the US office in Houston, Texas. Dr Shetty was the Director of Clinical Operations at Visualase, and a key member of the executive team which led the Houston-based medical startup to a $110 million Medtronic acquisition. He has also led development of products for epilepsy, spinal tumors, radiation necrosis and prostate cancer, and developed a network of clinics offering MRI guided biopsy and focal therapy for prostate cancer. He has a fellowship from MD Anderson Cancer Center and a Biomedical Engineering degree from Texas A&M. He has co-authored 30+peer-reviewed publications in oncology, radiology, neurology and neurosurgery.
Dr Aidan Cousins, Lead Engineer
Aidan has a strong background in experimental physics, with his PhD centred around bioengineering and medical devices. During his PhD, Aidan developed the novel handheld magnetic probe device for mapping lymphatic spread of metastases, which spawned the formation of Ferronova in 2016.
Aidan attended the University of South Australia, where he completed a Bachelor of Education, Bachelor of Science (Hons) in 2010, and his PhD in Materials and Minerals at the flagship Future Industries Institute (formerly Ian Wark Research Institute) in 2016.
Dr Melanie Nelson, Chemist
Melanie received her PhD in Chemistry from Victoria University of Wellington in 2015. Her PhD research in organometallic chemistry addressed the development of new bulky phosphine ligands and their interactions with late transition metals.
Melanie has a varied background in both experimental and theoretical chemistry, bridging organic, organometallic, and nanotechnology. During her scientific career Melanie has gained experience both in academic institutions and industry including the Technical University of Munich and Industrial Research Ltd.
Prof Benjamin Thierry, Scientific Advisor
Benjamin is a Research Leader at UniSA's Future Industries Institute where he leads the translational NanoBioEngineering group which aims to develop and implement novel cancer biodiagnostic and prognostic technologies.
He received his PhD in Biomedical Engineering from McGill University in 2004. He then took up a postdoctoral position at the Ian Wark Research Institute of the University of South Australia. He was promoted to Research Associate Professor in 2012 and has received prestigious awards including Career Development Award Fellowships from the NHMRC.
Dr Richard Tilley, Scientific Advisor
Richard is the Director of the Electron Microscope Unit at The University of New South Wales. His research is focused on the solution synthesis of nanoparticles and quantum dots for applications ranging from catalysis to biomedical imaging.
He did his PhD in the Department of Chemistry, University of Cambridge, UK, after which he was a Postdoctoral Fellow for two years at the Toshiba basic R&D Center, Japan. A native of the UK, he graduated with a Masters of Chemistry from Oxford University, UK.